Table 2.
Prognostic and predictive value of different genetic tests in breast cancer
| ASCO 2017 [1] | NCCN 2017 [2] | St Gallen 2017 [3] | SEOM 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prognosis | CT benefit prediction | Prognosis | CT benefit prediction | Prognosis | CT benefit prediction | Prognosis | CT benefit prediction | ||||
| 5 years | 10 years | 5 years | 10 years | 5 years | 10 years | ||||||
| Oncotype DX® | Yes | NA | Yes | Yes | Yes | +++ | +++ | Yes |
IA (low RS) IB (other RSs) |
IB |
IA (low RS) IB (other RSs) |
| Prosigna® | Yes | Yes | Yes | Yes | NA | ++ | ++ | Yes | IB | IB | NA |
| MammaPrint® | Yes | No | Yes | Yes | NA | +++ | NA | Yes | IB | NA | NA |
| EndoPredict® | Yes | Yes | Yes | Yes | NA | ++ | ++ | Yes | IB | IB | NA |
ASCO American Society of Clinical Oncology, CT chemotherapy, ESMO European Society for Medical Oncology, NA not available, NCCN National Comprehensive Cancer Network, RS Recurrence Score, SEOM Spanish Society of Medical Oncology